Interestingly, everolimus inhibited the propensity of dendritic cells to acquire osteoclast activity by blocking IL-17A receptor-driven signals [71], which further supports the hypothesis of an important role of IL-17 in bone diseases in MM. This evidence concerns the gene IL17RA and Miyoshi myopathy.